open access
RAGE and ADAM17 genes expression in peripheral blood monocytes in patients with type 2 diabetes. Implications of rosiglitazone therapy
open access
Abstract
Material and methods. Monocytes were isolated from peripheral blood samples taken before and after 22 weeks of rosiglitazone therapy, from 45 patients with type 2 diabetes. Expression of RAGE and ADAM17 genes was assessed with RT-PCR (ABI Prism 7900HT Sequence Detection System). Gene expression in the study group was determined in comparison with patterns obtained from 22 healthy volunteers. Others tests were conducted by means of routine lab assays.
Results. ADAM17 gene expression was detected in 78% of patients and RAGE gene in 71% in the study group as compared to control group. Rosiglitazone therapy did not result in a significant change in both genes’ expression (log RQ for ADAM17 before treatment 1.34 ± 1.11 vs. after treatment 1.20 ± 0.94; p = 0.464, and log RQ for RAGE 0.986 ± 1.02 vs. 1.17 ± 0.96; p = 0.675). Significant HbA1c reduction was observed after rosiglitazone therapy (before treatment 7.32 ± 1.76% vs. after treatment 6.69 ± 1.02%; p = 0.039).
Conclusions. Rosiglitazone therapy and improved glycaemic control in type 2 diabetes does not influence expression of ADAM17 and RAGE genes in peripheral blood monocytes.
Acta Angiol 2011; 17, 1: 98–108
Abstract
Material and methods. Monocytes were isolated from peripheral blood samples taken before and after 22 weeks of rosiglitazone therapy, from 45 patients with type 2 diabetes. Expression of RAGE and ADAM17 genes was assessed with RT-PCR (ABI Prism 7900HT Sequence Detection System). Gene expression in the study group was determined in comparison with patterns obtained from 22 healthy volunteers. Others tests were conducted by means of routine lab assays.
Results. ADAM17 gene expression was detected in 78% of patients and RAGE gene in 71% in the study group as compared to control group. Rosiglitazone therapy did not result in a significant change in both genes’ expression (log RQ for ADAM17 before treatment 1.34 ± 1.11 vs. after treatment 1.20 ± 0.94; p = 0.464, and log RQ for RAGE 0.986 ± 1.02 vs. 1.17 ± 0.96; p = 0.675). Significant HbA1c reduction was observed after rosiglitazone therapy (before treatment 7.32 ± 1.76% vs. after treatment 6.69 ± 1.02%; p = 0.039).
Conclusions. Rosiglitazone therapy and improved glycaemic control in type 2 diabetes does not influence expression of ADAM17 and RAGE genes in peripheral blood monocytes.
Acta Angiol 2011; 17, 1: 98–108
Keywords
RAGE; ADAM17; monocytes; diabetic macroangiopathy; rosiglitazone
About this articleTitle
RAGE and ADAM17 genes expression in peripheral blood monocytes in patients with type 2 diabetes. Implications of rosiglitazone therapy
Journal
Issue
Article type
Research paper
Pages
98-108
Published online
2011-04-22
Page views
856
Article views/downloads
2168
Bibliographic record
Acta Angiologica 2011;17(1):98-108.
Keywords
RAGE
ADAM17
monocytes
diabetic macroangiopathy
rosiglitazone
Authors
Małgorzata Gacka
Anna Sadakierska-Chudy
Tadeusz Dobosz
Stanisław Szymaniec
Dorota Bednarska-Chabowska
Rajmund Adamiec